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Introduction
Holoprosencephaly (HPE1, OMIM #236100) is a severe developmental defect resulting from incomplete forebrain cleavage. The disease is characterized by incomplete separation of cerebral hemispheres with several anatomical classes ranging from microforms to alobar HPE. Affected individuals present with typical craniofacial midline defects of varying severity including proboscis, cleft lip and palate, ocular hypotelorism and solitary median incisor. HPE occurs in about 1 in 10 000 to 20 000 live births worldwide .
The genetic basis of HPE remains unclear and different transmission patterns have been described including autosomal dominant, recessive and digenic inheritance (Dubourg et al., 2018) . Most mutations associated with HPE display incomplete penetrance and variable expressivity, i.e. close relatives carrying the same pathogenic variant can be asymptomatic or present distinct HPE-spectrum anomalies . Sonic hedgehog (SHH) was the first discovered gene implicated in HPE (Roessler et al., 1996) and its variants remain the most common cause of non-chromosomal HPE (Dubourg et al., 2018) . In 2011, molecular screening of 645 HPE probands revealed that mutations in the SHH, ZIC2, SIX3 and TGIF1 genes were the most frequent ones and collectively accounted for 25% of cases . The following studies reported that GLI2 might also be considered as a major HPE gene in terms of frequency , although variants in GLI2 rarely result in classic HPE but instead cause a distinct phenotype that includes pituitary insufficiency and subtle facial features (Bear et al., 2014) . Pathogenic variants in FGF8, FGFR1, DISP1, and DLL1 were also found in $7% of HPE cases (Dupé et al., 2011; Dubourg et al., 2016) . The other HPE genes reported so far are TDGF1, FOXH1, TGIF1, CDON, NODAL, GAS1, STIL and SUFU whose frequency is not established due to the small number of reported cases (Mouden et al., 2015 Dubourg et al., 2018; Kruszka et al., 2018) .
Clinical genetic testing of HPE has improved, but $70% of familial cases remain without a clear molecular diagnosis. Most of known HPE genes belong to the SHH pathway, which represents the primary pathway implicated in the disease (Mercier et al., 2013; Dubourg et al., 2016; Kruszka et al., 2018) . Therefore, defective SHH-related processes are likely to be substantially involved in HPE.
Whole-exome sequencing (WES) has been successful for Mendelian disease-gene discovery and differential diagnosis (Bamshad et al., 2011) . WES analysis uses filtering approaches for candidate variant prioritization combined with comprehensive clinical evaluation. A variety of additional strategies has been developed to further improve the performance of WES in clinical settings. Collaborative platforms such as Matchmaker Exchange (Philippakis et al., 2015) are used to search for recurrence in patients affected by similar phenotypes. Integrative variant-prioritization algorithms such as the Exomiser suite (Smedley et al., 2015) combine WES with different phenotype-driven approaches (based on clinical data and cross-species phenotype comparisons) and analysis of protein interactome data. As useful as they are, these strategies are limited: collaborative platforms are not efficient in case of very rare genetic diseases while pipelines such as Exomiser are not designed to study non-Mendelian disorders. Studying HPE faces these two challenges: (i) HPE live-born infants are excessively rare; and (ii) although HPE is considered a Mendelian disorder, the wide range of severity must necessitate strong modifying factors such that a single pathogenic variant may be neither necessary nor sufficient for pathogenesis.
Recent studies have highlighted that non-Mendelian disease phenotypes could present an oligogenic aetiology and result from accumulation of inherited low-penetrance variants in multiple genes (Li et al., 2017) . However, such events are likely overlooked in clinical genetic studies if variants are inherited from a clinically unaffected parent.
In this study, we address the additional yield that can be obtained for HPE patients who underwent medical WES evaluation in clinical settings that failed to establish a molecular diagnosis. Given the wide clinical spectrum of the disease, as well as incomplete penetrance and variable expressivity of HPE mutations, we raised the possibility that the low diagnostic yield is partly due to the complex aetiology of HPE and hypothesized that a part of unsolved HPE cases results from oligogenic events, i.e. accumulation of several rare hypomorphic variants in distinct, functionally connected genes.
Our study involved patients for whom no disease aetiology could be determined by conventional diagnostic approaches. Similarly to previous WES studies ( Lee et al., 2014; Stark et al., 2017) , we used clinically-driven prioritization approach to identify genes associated with specific clinical features as reported in gene-phenotype reference databases and mouse models. Complementarily, we developed and used a prioritization strategy based on gene co-expression networks of the developing human brain to select genes with spatio-temporal expression patterns compatible with those of known HPE genes. Finally, we used in-depth clinical phenotyping together with cross-species similarities to further strengthen the evidence of causality.
This study highlights novel HPE genes and identifies new disease-related pathways including the primary cilia pathway. Our findings also illustrate the high degree of oligogenicity of HPE and suggest that the disease requires a joint effect of multiple hypomorphic mutations.
Materials and methods

Patient selection and preliminary genetic analyses
Study protocol was approved by the Ethics Committee of Rennes Hospital. Patients diagnosed with HPE and relatives were recruited using the clinical database of Holoprosencephaly Reference Center of Rennes Hospital. Study participation involved informed written consent, availability of clinical data, and either DNA or peripheral blood sample.
The main selection criterion for this study was the absence of clear genetic cause of HPE after conventional diagnostic procedures. As part of routine diagnosis, all patients were scanned for rare damaging mutations by targeted HPE genepanel sequencing and for copy number variants (CNVs) using comparative genomic hybridization (CGH)-array and multiplex ligation-dependent probe amplification (MLPA). Patients for whom no genetic cause of HPE (i.e. a fully-penetrant causal mutation in known HPE gene or a chromosomic aberration/copy number variant explaining the pathology) could be established, underwent trio-based WES for further analysis. WES was performed using standard procedures as previously described (Mouden et al., 2015 . The scheme for variant classification followed the American College of Medical Genetics and Genomics association (ACMG) guidelines (Richards et al., 2015) and included a hypothesis-free analysis of all de novo and homozygous variants on a family-by-family basis. Patients for whom no such variants of clinical interest had been detected were considered eligible for the hypothesis of oligogenic inheritance and included in this study.
Variant selection under oligogenic hypothesis
As discussed in previous studies, ACMG guidelines are useful in identifying variants with strong effect on phenotype but are unhelpful in case of modifier variants (Hong et al., 2017) . Therefore, the ACMG classification was not taken into account for variant selection dedicated to the analysis of oligogenic events. WES trio data were reanalysed using more permissive settings (filtering protocols used in this study are described in the Supplementary material). The exome analysis was complemented with two gene prioritization strategies based on available clinical knowledge and co-expression networks.
Clinically-driven approach
We established two clinician-generated lists of relevant phenotypes reminiscent of HPE in human and mouse models, respectively (Supplementary Table 3 ). Genes associated with the phenotypes of interest were identified with publicly available clinical resources and associated ontologies. Human genephenotype associations were extracted from relevant databases ( Supplementary Fig. 1 ) using R package VarFromPDB (https:// github.com/cran/VarfromPDB). The Mouse Genome Informatics (MGI) (Smith et al., 2018) database and a homemade workflow were used to retrieve genes associated with any of the corresponding phenotypes in mouse mutants. Human and mouse results were combined and redundancy was removed to establish a list of clinically-driven candidate genes associated with HPErelated anomalies (Supplementary Table 4 ).
Identification of HPE-related genes by weighted gene co-expression network analysis
We used weighted gene co-expression network analysis (WGCNA) (Langfelder and Horvath, 2008) on the RNA-Seq data from the Human Development Biology Resource (HDBR) (Lindsay et al., 2016) to identify genes sharing highly similar expression patterns with four classical genes associated with HPE (SHH, SIX3, ZIC2 and TGIF1) during cerebral development. Data from samples corresponding to forebrain, cerebral cortex, diencephalon, telencephalon and temporal lobe structures taken between the fourth and 10th post-conception weeks were selected ( Supplementary Fig. 9 ). RNA-seq data were analysed with the iRAP pipeline (https://github.com/ nunofonseca/irap). We used R package WGCNA to construct co-expression networks and identify modules of co-expressed genes. The detailed protocols for WGCNA analysis are described in the Supplementary material. The Topological Overlap Matrix (TOM) matrix was used to establish a list of transcriptome-driven candidate genes sharing highly similar expression profiles with SHH, ZIC2, SIX3 and TGIF1 (Supplementary Table 5 ).
Integration and identification of oligogenic events
The two gene prioritization schemes were combined with the WES results to identify a restricted list of rare variations located in genes identified by either the transcriptomic or the clinical prioritization approach (Fig. 1) . Further analyses of the candidate variants were performed on a family-by-family basis. Oligogenic events were defined as combinations of candidate variants in 52 genes co-segregating with disease, i.e. unique to the affected individuals of each family. Variants could be either inherited from the parents-at least one each from the mother and the father-or occur de novo in the affected child.
To evaluate the impact of candidate genes further, we performed deep clinical phenotyping to characterize similarities between unrelated patients and/or published knockout mice. Special attention was given to genes harbouring distinct rare variants in at least two affected patients with striking phenotypic overlap. Phenotypic overlaps between patients and mouse mutants deficient for the corresponding candidate genes were also examined. The most interesting oligogenic combinations of rare deleterious variants in the affected children were finally discussed during multidisciplinary meetings.
To determine significantly enriched biological processes and pathways, functional annotation was performed by g:profiler (http://biit.cs.ut.ee/gprofiler) and Bonferroni adjusted P-value were considered significant below a value of 0.05 (KEGG, REACTOME and Gene Ontology Biological Processes). 
Control cohorts and validation
To test whether the identified oligogenic combinations were specific to the HPE cohort, we used SNV and INDELS data from 248 healthy trios (744 individuals) provided by Genome of the Netherlands (GoNL) sequencing project as a control cohort (Genome of the Netherlands Consortium, 2014). Additional control cohort consisting of 574 unrelated French individuals was provided by the French Exome Project (FREX).
We applied the same variant filtering approach and the same strategy for selection of oligogenic events. Proportion of families and/or individuals presenting oligogenic events were then compared between HPE cohort and the control cohorts. P-values were calculated using two-sided Fisher's exact test (fisher.test function in R, version 3.4.2).
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Results
Clinical findings
We assembled a cohort of 26 families representing a total of 80 individuals including 29 affected children diagnosed with lobar (n = 3), semilobar (n = 11), alobar (n = 13) or microform HPE (n = 2) ( Table 1) . Common HPE clinical manifestations were observed among the probands and included cleft lip and palate (38%), hypotelorism (34%), microcephaly (31%) and arhinencephaly (31%). Ancestry analysis identified that 24 families were of European descent and two of South East Asia and African descent ( Supplementary Fig. 10 ). Eight parents presented minor signs of midline facial anomalies and three parents were diagnosed with HPE microforms.
The initial targeted sequencing had identified point mutations in known HPE genes in 13 families and a full heterozygous deletion of SIX3 gene had been detected by CGHarray in one family ( Fig. 2 and Supplementary Fig. 8 ). All anomalies were later confirmed by WES analysis. They were inherited from asymptomatic or mildly affected parents and were considered as insufficient to fully explain the pathogenesis of HPE, suggesting that the presence of additional risk factors was required for the disease to occur.
HPE variants overview and identification of disease-related pathways
Combined clinically-and transcriptome-driven analysis of the exome data identified a total of 232 rare candidate variants in 180 genes ( Fig. 1 and Supplementary Table 6 ). All variants presented a minor allele frequency below 1% and were predicted to be highly deleterious to protein function (Supplementary material). One hundred and fifty-three variants concerned genes associated with HPE phenotypes among which 32 were located in genes reported to induce HPE-like phenotypes in mutant mice (Supplementary Table 8 ). One hundred and two variants were located in genes sharing expression profiles highly similar to those of HPE genes. Overlap between phenotype and gene co-expression network analysis contains 23 variants including 14 previously described mutations in known HPE genes (SHH, ZIC2, SIX3, GLI2, TGIF1 and PTCH1). Consistent with known disease aetiology, functional profiling of the 180 genes revealed a significant enrichment for biological processes implicated in forebrain development (Supplementary Table 7) including Sonic Hedgehog signalling pathway (REAC:5358351, P-value = 2.79 Â 10 ) and Wnt/Planar Cell Polarity (PCP) signalling pathway (GO:0016055, Pvalue = 2 Â 10 -5
). The SHH pathway is the primary pathway implicated in HPE and the primary cilium is required for the transduction of SHH signalling (Gorivodsky et al., 2009; Murdoch and Copp, 2010 ) while components of Wnt/PCP pathway regulate both SHH signalling and primary cilia (Goetz et al., 2009; Murdoch and Copp, 2010) .
In-depth analyses highlighted 10 families with oligogenic events (Fig. 2) clustered among 19 genes ( Tables 2 and 3) that functionally relate to disease-relevant pathways (Fig. 3) . These combinations of variants were unique to the affected probands. The main findings are presented below and full reports are available in the Supplementary material.
Recurrent oligogenic events involving FAT1
Four different families, i.e. 15% of the 26 families studied here, presented oligogenic events involving FAT1 in combination with rare variants in known HPE genes (SHH, PTCH1), as well as in NDST1, COL2A1 and LRP2 Tables 2, 3 and Supplementary Table 6 . (A) Oligogenic events involving FAT1. (B) Oligogenic events involving variants in SCUBE2 and BOC. (C) Oligogenic events involving mutations in genes related to the primary cilium. *Not available for WES, clinical phenotyping and Sanger sequencing of SHH, FAT1 and NDST1 were performed. **Samples not available, Sanger sequencing of SHH was performed in the referring laboratory. b genes ( Fig. 2A) . FAT1 is a protocadherin and its knockdown in mice causes severe midline defects including HPE (Ciani et al., 2003) ; in Drosophilia it has been shown to regulate the PCP pathway (Rock et al., 2005) . LRP2, NDST1 and COL2A1 are all functionally relevant to the SHH pathway ( Fig. 3 ): NDST1 and COL2A1 mice mutants exhibit HPE phenotype and reduced SHH signalling in the forebrain (Grobe et al., 2005; Leung et al., 2010) , while LRP2 acts as an auxiliary receptor of SHH during forebrain development and its inactivation in mouse similarly leads to HPE phenotype (Christ et al., 2012) . Oligogenic events involved the following combinations: SHH/FAT1/NDST1 (Family F3), FAT1/NDST1/COL2A1 (Family F16), FAT1/COL2A1/PTCH1 (Family F26) and FAT1/LRP2 (Family F23) ( Fig. 2A, Tables 2 and 3 ). Details are provided in the Supplementary material, Case report 1.
In Family F3, Sanger sequencing of additional family members revealed that the SHH/FAT1/NDST1 combination was unique to the affected individuals ( Fig. 2A) . For Family F16, only the foetus carrying the FAT1/NDST1/COL2A1 combination was affected by semilobar HPE, while the sibling carrying NDST1/COL2A1 variants presented only a microform ( Fig. 2A) . These observations are fully consistent with the oligogenic inheritance model where accumulation of multiple variants in genes associated to HPE phenotypes and/or HPE-related molecular pathways is required.
Recurrent oligogenic events involving SCUBE2/BOC implicated in SHH signalling
Two families presented oligogenic events implicating combined variants in the BOC and SCUBE2 genes (Fig. 2B , Tables 2 and 3) . BOC is an auxiliary receptor of SHH and was recently reported as an HPE modifier in humans (Hong
Primary Cilia et al., 2017). SCUBE2 shares a highly similar expression pattern with SHH and SIX3 and is implicated in the release of SHH from the secreting cell (Jakobs et al., 2014) . In Family F4, a combination of SCUBE2/BOC variants was associated with additional variants in SHH, STK36 (see below) and WNT4, a member of the Wnt pathway, implicated in regulation of SHH signalling (Murdoch and Copp, 2010) . In Family F22, the SCUBE2 variant results in a premature stop codon at position 525 ( Supplementary  Fig. 7) , which results in truncation of its CUB domain and is predicted to directly affect its SHH-related activity (Jakobs et al., 2014) . This family presented an additional candidate variant in HIC1, which genetically interacts with PTCH1 (Briggs et al., 2008) . Mice deficient for HIC1 exhibit craniofacial defects including HPE (Carter, 2000) . The reported variant combinations were observed exclusively in the affected probands and were absent in asymptomatic individuals. Altogether, these results reveal recurrent mutations in SCUBE2/BOC and further strengthen the oligogenic inheritance model of HPE.
Implication of primary cilium in HPE
Remarkably, five families presented candidate variants in genes related to the primary cilium: STK36, IFT172, B9D1, MKS1, TCTN3 and TULP3 (Fig. 2C) . Ciliary proteins are known to play essential roles in the transduction of SHH signalling downstream of PTCH1 during forebrain development (Goetz et al., 2009; Murdoch and Copp, 2010) .
STK36, also known as 'fused', is a ciliary protein implicated in SHH signalling and associated to craniofacial phenotypes (Goetz et al., 2009; Murdoch and Copp, 2010) . IFT172 codes for a core component of intraflagellar transport complex IFT-B required for ciliogenesis and regulation of SHH signal transduction. Moreover, Ift172 -/-mice exhibit reduced expression of Shh in the ventral forebrain and severe craniofacial malformations including HPE (Gorivodsky et al., 2009) . B9D1, MKS1 and TCTN3 are all members of the transition zone protein complex implicated in regulation of ciliogenesis (Garcia-Gonzalo et al., 2011) . The disruption of B9d1 and Mks1 in mouse models causes craniofacial defects that include HPE (Dowdle et al., 2011; Wheway et al., 2013) . Although no mouse model is available for TCTN3, its expression profile is highly similar to that of SHH and disruption of its protein complex partners (TCTN1, TCTN2, CC2D2A, MKS1, B9D1) leads to HPE in mouse (Dowdle et al., 2011; Garcia-Gonzalo et al., 2011; Wheway et al., 2013) . Moreover, TCTN3 was shown to be necessary for the transduction of SHH signal and TCTN3 mutations were found in patients affected by ciliopathies (Thomas et al., 2012) . Finally, TULP3 is a critical repressor of Shh signalling in mice and is associated with various craniofacial defects (Murdoch and Copp, 2010) .
Additional variants observed in these families include a heterozygous deletion of SIX3, missense mutations in SHH, SCUBE2, BOC and LRP2 (described above) as well as two genes implicated in PCP pathway (Fig. 3) : CELSR1 (two families) and PRICKLE1, both associated with craniofacial defects in mouse mutants (Fig. 2C) (Goetz et al., 2009; Murdoch and Copp, 2010; Yang et al., 2014) . Similar to previously described cases, the oligogenic events were present exclusively in the affected children.
Given the essential role of the primary cilium in SHH signal transduction, these observations strongly suggest that rare variants in ciliary genes contribute to the disease onset in these families.
Correspondence between affected genes and secondary clinical features
To provide additional evidence, we performed an in-depth analysis of secondary clinical features associated with HPE in our patients. Deep clinical phenotyping identified clinical similarities between unrelated patients (Tables 2 and 3) as well as overlaps of secondary clinical features between patients and the corresponding mouse mutants.
Interestingly, the two patients with variants in ciliary genes (IFT172/PRICKLE1 and SIX3/TCTN3/TULP3) both presented with polydactyly, a clinical feature commonly associated with ciliopathies (Goetz et al., 2009) . Importantly, the patient with the oligogenic combination IFT172/PRICKLE1 presented with a large set of overlapping clinical features with the corresponding mouse mutants including polydactyly, cleft palate and eye defects (Gorivodsky et al., 2009; Yang et al., 2014) .
Of note, the two unrelated patients having variants in FAT1 and NDST1 shared a large set of specific secondary clinical features, including mandibular and ear abnormalities. Intrauterine growth restriction was found exclusively in the two patients with COL2A1 variants. The most severely affected child in Family F16 (FAT1/NDST1/ COL2A1) presented a strong overlap with NDST1-null and COL2A1-null mutant mice (HPE, mandibular anomalies, absent olfactory bulb, abnormal nose morphology) (Grobe et al., 2005; Leung et al., 2010) . Similarly, proboscis and eye defects were observed in both FAT1/NDST1/ SHH patient and FAT1 -/-mice (Ciani et al., 2003) . Finally, the two unrelated SCUBE2/BOC cases in Families F4 and F22 presented with cebocephaly, a midline facial anomaly characterized by ocular hypotelorism and a single nostril, which was absent in all other patients. Consistently, SCUBE2 is highly expressed in the nasal septum in mouse (Xavier and Cobourne, 2011) , and cebocephaly was previously associated with CDON-another known HPE gene sharing highly similar functions and structure with BOC (Zhang et al., 2006) .
While these clinical features are not specific to HPE, the described overlaps provide additional support for disease implication of the presented candidate variants.
Statistical validations
The identified oligogenic events were clustered among 19 genes (Fig. 2, Tables 2 and 3) . To assess the frequency of healthy individuals presenting similar variant combinations in these genes, we applied the same family-by-family variant analysis to the 248 control trios provided by GoNL. This control cohort was chosen as 24/26 (92%) of the HPE families included in the study were of European descent ( Supplementary Fig. 10 ).
The approach identified three families among controls presenting variant combinations satisfying the criteria that we established for the oligogenic events (gene, variant and parental inheritance). The three oligogenic events found in the control cohort were FAT1/B9D1, SCUBE2/PTCH1 and SCUBE2/LRP2/PTCH1/CELSR1 (Supplementary Table 9 ). Although one SCUBE2 variant (p.Thr285Met) was found in both the HPE and the control cohort, none of the combinations found among controls corresponded to oligogenic events identified in the HPE cohort. The incidence of oligogenic events was significantly lower in the GoNL families (3/248, 1.2%) as compared to the HPE cohort (10/26, 38%) with a Fisher's exact test P-value of 2.301 Â 10 -9 (Table 4) .
Three additional children of the GoNL cohort harboured combinations of rare deleterious variants in two or more candidate genes. However, in these cases, all variants were inherited from the same parent. Therefore, these combinations were not considered as oligogenic events similar to those of HPE patients. Nevertheless, even when taking into account these three additional cases, the proportion of children having variants in two or more candidate genes was significantly different between the HPE cohort (13/29, 45%) and the GoNL cohort (6/248, 2.4%) with a Fisher's exact test P-value of 1.902 Â 10 -10 . Finally, 14 individuals of the GoNL cohort (parents and children combined) harboured rare deleterious variants in two or more genes. Without taking into account the relatedness between the GoNL individuals, the proportion of individuals having variants in two or more candidate genes remained significantly different between the HPE cohort (21/80, i.e. 26%) and the GoNL control cohort (14/744, 1.8%), as confirmed by Fisher's exact test ). To assess the frequency of control individuals presenting rare variant combinations in the identified candidate genes further (Fig. 2, Tables 2 and 3 ), we analysed a second control cohort. The FREX data were chosen as they consist of 574 unrelated French individuals ancestrally matching the HPE cohort.
Screening of the FREX cohort revealed that 16/574 individuals (i.e. 2.7%) harboured rare deleterious variants in two or more candidate genes. This proportion was statistically different from that observed in the HPE cohort (21/ 80, 26% versus 16/574, 2.7%; P-value = 1.521 Â 10 -11 , Fisher's exact test).
Additionally, the two control cohorts (GoNL and FREX) did not present statistically significant differences in terms of proportions of individuals having rare deleterious variants in two or more candidate genes: 14/744 (1.8%) for the GoNL cohort versus 16/574 (2.7%) for the FREX (Pvalue = 0.35, Fisher's exact test).
The analysis of the GoNL and FREX cohorts illustrates that the incidence of combined rare deleterious variants in the identified candidate genes is significantly higher in HPE patients as compared to a control population. All performed comparisons showed a statistically significant Pvalue between the cases and the controls (Table 4) , thus providing evidence for oligogenicity as clinically relevant model in HPE.
Discussion
In this study, we addressed the relevance of oligogenic model for unsolved HPE cases. We provide evidence that the onset of HPE arises from the combined effects of hypomorphic variants in several genes belonging to critical biological pathways of brain development. To circumvent the limitations of classical WES analysis in complex rare disorders, we combined clinically-driven and co-expression network analyses with classical WES variant prioritization. This strategy was applied to 26 HPE families and allowed prioritization of 180 genes directly linked to the SHH signalling, cilium and Wnt/PCP pathways (Fig. 3) . The analysis of oligogenic events in patients with HPE anomalies revealed 19 genes including 15 genes previously unreported in human HPE patients (Tables 2 and 3 ). All these genes Oligogenic inheritance is defined as presence of combined rare deleterious variants in two or more genes, described in Table 3 and Fig. 2 . The proportion of individuals harbouring combined rare deleterious variants in the identified genes is significantly higher in HPE cohort as compared to two control populations GoNL and FREX (Fisher's exact test).
are either associated with HPE phenotypes in corresponding mouse models (such as FAT1, NDST1), present highly similar expression patterns with already known HPE genes in the developing brain (such as SCUBE2, TCTN3), or both. We observed co-occurrence of mutations in several gene pairs such as FAT1/NDST1 and SCUBE2/BOC, which provides additional arguments towards their implication in HPE. The incidence of oligogenic combinations was significantly higher in HPE patients compared to the GoNL and FREX control populations. We additionally show that in-depth evaluation of secondary clinical features in patients with HPE anomalies and comparison to published mouse knockout models may provide additional arguments for the causality of candidate genes.
The main challenge in disease-gene discovery by WES is to identify disease-related variants among a large background of non-pathogenic polymorphisms (Bamshad et al., 2011; MacArthur et al., 2014) . For example, the presented FAT1 encodes a large protocadherin gene spanning over 139 kb in the human genome and presenting over 2000 missense variants with a minor allele frequency below 1% in the gnomAD database. Despite this high number of variations found in the general population, rare variants in FAT1 were recently implicated in several genetic disorders including facioscapulohumeral dystrophy-like disease (Puppo et al., 2015) . Hence, correct interpretations and conclusions require extremely careful assessment of available biological and clinical knowledge.
To improve the pertinence of our study, we developed a strategy to restrict the potential candidates by targeting genes with biological and clinical arguments for their implication in the disease. Implication of a given gene in a disease is often supported by the similarity between the human pathology and the phenotype obtained in relevant animal models (MacArthur et al., 2014) . Accordingly, in this study, the main evidence of causality for candidate genes was that their disruption leads to clinically-defined HPE-related phenotypes in corresponding published mutant mouse models. Unlike other phenotypes, such as reduced body weight (Reed et al., 2008) , holoprosencephaly is a rare effect of gene knockout in mice as it is associated with 51% of knockout mice (as reported in the MGI database). Recent exome sequencing studies have applied similar phenotype-driven approaches to identify causal variants in monogenic disorders. Dedicated tools have been developed to that aim (Exomiser, Phive) (Smedley et al., 2015) but none are designed for nonMendelian traits involving hypomorphic variants with mild effects. We provide a method to specifically address such cases and show that further developments are necessary to improve the diagnosis of genetic disorders, especially by taking into account oligogenic inheritance. Inclusion of carefully defined mouse mutant phenotypes is of powerful value as certain phenotypes like HPE are very informative due to their rarity.
Prioritization tools can also include protein-protein interaction (PPI) network information, which improves performance in cases where candidate genes do not have an associated knockout mouse model. However, PPI-based prioritization is limited when disease investigation requires incorporation of tissue-specific data. The key process affected by HPE is the elaboration of the forebrain and its dorso-ventral patterning (Fernandes and Hébert, 2008) . Deciphering the biological mechanisms involved in the early brain development is therefore necessary to provide relevant information to select disease-related genes. To incorporate tissue-specificity, we performed analysis using the RNA-Seq data of embryonic human brain at the earliest available developmental stages (from 4 to 17 post-conception weeks) as provided by the Human Development Biology Resource (Lindsay et al., 2016) . We defined relevant co-expression modules and selected candidate genes of which expression patterns follow those of known HPE genes. Further analysis showed that the resulting candidate genes, such as SCUBE2 and TCTN3, are pertinent as they are equally implicated in the SHH pathway that is the primary HPE pathway (Thomas et al., 2012; Jakobs et al., 2014) . Co-expression analysis provides additional insight into disease pathogenesis by establishing the first link between previously unrelated genes. A future challenge will be to generalize this approach, but such a task will face the necessity to incorporate disease relevant co-expression modules that need to be pre-computed.
Patients exhibiting HPE anomalies present enrichment of rare variants in genes related to the SHH pathway, as well as to the Wnt/PCP and primary cilia pathways, which were both shown to functionally interact with and regulate SHH pathway (Goetz et al., 2009; Gorivodsky et al., 2009; Murdoch and Copp, 2010; Wheway et al., 2013) . Accumulation of multiple rare variants in genes related to these pathways will likely disrupt the dorso-ventral gradient of the SHH morphogen (Fernandes and Hébert, 2008) , leading to an incomplete cleavage of the forebrain and, ultimately, to HPE. In this model, distinction between different manifestations of HPE lies in the degree of overall functional impact on SHH signalling (Mercier et al., 2013) . Moreover, depending on the affected genes and pathways, HPE patients would present different secondary clinical features.
The observed overlapping secondary clinical features further support the causality of the reported variants for HPE. As hypomorphic mutations do not have the same impact as the complete inactivation of a gene in most cases, phenotypic overlaps may be challenging to detect and require expert assessment of clinical and biological data. For example, mice deficient in NDST1 exhibit agnathia (Grobe et al., 2005) (absence of the lower jaw) while unrelated patients presenting candidate variants in NDST1 exhibit prognathia and retrognathia (abnormal positioning of the lower jaw), respectively. All three phenotypes are part of the same spectrum of mandibular anomalies. From a clinical perspective, overlap of secondary clinical features between the patient and the animal models provides additional critical evidence of a causal relationship between candidate gene and disease. A key issue here remains the semantic representation of patient's phenotype and the use of a well-established phenotypic ontology during the examination processes. Explorations of secondary clinical features should be performed in future studies of genetic diseases.
Additional molecular screenings in larger populations of HPE patients are necessary to definitely assess the implication of our candidate genes in the disease. Therefore, we propose to include these novel genes into future genetic screenings of HPE patients.
In conclusion, this paper presents novel genes implicated in HPE and illustrates that HPE presents an oligogenic inheritance pattern requiring the joint effect of multiple genetic variants acting as hypomorphic mutations. The proposed inheritance pattern accounts for a wide clinical spectrum of HPE and explains the significant part of cases in which no molecular diagnosis could be established by conventional approaches. It also explains the incomplete penetrance and variable expressivity of inherited causal mutations observed in the reported cases of HPE . We propose that in cases of non-Mendelian diseases with variable phenotypes, the possibility of oligogenic inheritance needs to be evaluated. Exploration of such events will improve the diagnostic yield of complex developmental disorders and will contribute to better understanding of the mechanisms that coordinate normal and pathological embryonic development.
